Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.

Lück, H J; Thomssen, C; du Bois, A; Untch, M; Lisboa, B; Köhler, G; Diergarten, K

Lück, H J; Thomssen, C; du Bois, A; Untch, M; Lisboa, B; Köhler, G; Diergarten, K.

Affiliation

Lück HJ; Department of Gynecologic Oncology, Frauenklinik der Medizinischen Hochschule, Hannover, Germany.

Semin Oncol ; 24(5 Suppl 17): S17-35-S17-39, 1997 Oct.

Article in En | MEDLINE | ID: mdl-9374090

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Adult; Aged; Epirubicin/administration & dosage; Feasibility Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel/administration & dosage

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Guideline Limits: Adult / Aged / Humans / Middle aged Language: En Journal: Semin Oncol Year: 1997 Type: Article Affiliation country: Germany

Search on Google

XML

PubMed Links